Courtney Bailey

Professional with experience in clinical research coordination, equipped to make significant impact in this field. Demonstrated ability to manage clinical trials, ensure compliance with protocols, and maintain accurate documentation. Strong emphasis on team collaboration, reliability, and adaptability to evolving project requirements. Proficient in patient recruitment, data collection, and regulatory submissions, with results-driven approach that ensures successful study outcomes.

• Good Clinical Practice certified
• IATA certified

• Cosmetic
• A Phase 2 Study to Evaluate xxxx in Subject with Glabellar Lines
• XXXX for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
• A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of XXXX injectable gel for restoring jawline definition
• Clinical Trial to Evaluate XXXX in Subjects with Lateral Canthal Lines
• Alopecia Areata
• A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial of XXXX for the Treatment of Severe Alopecia Areata
• A multicenter, open-label, extension study to assess the long-term safety and efficacy of XXXX in adult patients with moderate severe alopecia areata
• A multicenter, randomized, double-blind, placebo controlled, Phase 3 study to evaluate the efficacy and safety of XXXX in adult patients with severe or very severe alopecia areata
• Androgenetic Alopecia
• A randomized, double-blind, placebo-controlled, parallel group, multi-dose study to evaluate the efficacy and safety of XXXX in male subjects with androgenetic alopecia
• Atopic Dermatitis
• Inflammatory Skin Disease Treatment Identification Study
• A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of XXXX in Subjects with Moderate-to-Severe Atopic Dermatitis
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of XXXX Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis
• A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of XXXX on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
• Actinic Keratosis
• A randomized, double-blind, vehicle-controlled, multicenter Phase III study to evaluate the safety and efficacy of XXXX and XXXX in the field-directed treatment of mild to moderate actinic keratosis on the face and scalp with photodynamic therapy (PDT).
• A randomized, double-blind, vehicle-controlled, multicenter Phase III study to evaluate the safety, tolerability, and efficacy of XXXX in the field-directed treatment of actinic keratosis on the extremities and neck/trunk with photodynamic therapy (PDT) using XXXX or XXXX lamp
• Basal Cell Carcinoma
• A randomized, double-blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of XXXX and XXXX in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). XXXX (topical gel) or placebo and PDT (red light)
• A Phase 2, Multicenter, Open-label, Proof-of-Concept Study with Safety Run in to Evaluate the Safety, Pharmacokinetics, and Efficacy of XXXX in Adult Subjects with Basal Cell Carcinoma
• Hidradenitis Suppurativa
• A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety XXXX in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
• Psoriasis
• A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of XXXX in Patients with Moderate to Severe Plaque Psoriasis
• An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to XXXX
• A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXXX Versus Placebo for the Treatment of Low BSA Moderate Plaque Psoriasis With Special Site Involvement
• A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of XXXX for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate to Severe Scalp Psoriasis
• A 16-week randomized evaluation of the impact of XXXX on response to biologic treatment in patients suffering from plaque psoriasis Through Clinical utility and Health outcomes.
• Efficacy and Tolerability of XXXX in Mild Psoriasis
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Moderate to Severe Plaque Psoriasis
• A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of XXXX Compared with Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis
• Verruca Vulgaris
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXX for the Treatment of Common Warts (Verruca vulgaris) in Adolescents and Adults
• A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXXX in Subjects with Verruca Vulgaris
• Vitiligo
• A Phase 3, Randomized, Double-Blind, 52-week, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of XXXX in Adult and Adolescent Participants with Non-Segmental Vitiligo
• A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXXX in Subjects with Non-Segmental Facial Vitiligo